These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33750748)

  • 21. Allopurinol Use During Maintenance Therapy for Acute Lymphoblastic Leukemia Avoids Mercaptopurine-related Hepatotoxicity.
    Giamanco NM; Cunningham BS; Klein LS; Parekh DS; Warwick AB; Lieuw K
    J Pediatr Hematol Oncol; 2016 Mar; 38(2):147-51. PubMed ID: 26808368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of Allopurinol in Optimizing Thiopurine Therapy in Patients with Autoimmune Hepatitis: A Review.
    Deswal S; Srivastava A
    J Clin Exp Hepatol; 2017 Mar; 7(1):55-62. PubMed ID: 28348471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0-45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol.
    Toksvang LN; Als-Nielsen B; Bacon C; Bertasiute R; Duarte X; Escherich G; Helgadottir EA; Johannsdottir IR; Jónsson ÓG; Kozlowski P; Langenskjöld C; Lepik K; Niinimäki R; Overgaard UM; Punab M; Räty R; Segers H; van der Sluis I; Smith OP; Strullu M; Vaitkevičienė G; Wik HS; Heyman M; Schmiegelow K
    BMC Cancer; 2022 May; 22(1):483. PubMed ID: 35501736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thiopurine methyltransferase deficiency in childhood lymphoblastic leukaemia: 6-mercaptopurine dosage strategies.
    Lennard L; Lewis IJ; Michelagnoli M; Lilleyman JS
    Med Pediatr Oncol; 1997 Oct; 29(4):252-5. PubMed ID: 9251729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of morning versus evening schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with acute lymphoblastic leukemia. Nordic Society for Pediatric Hematology and Oncology (NOPHO).
    Schmiegelow K; Glomstein A; Kristinsson J; Salmi T; Schrøder H; Björk O
    J Pediatr Hematol Oncol; 1997; 19(2):102-9. PubMed ID: 9149738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment on the use of allopurinol to improve safety and efficacy of mercaptopurine in pediatric patients with Acute Lymphoblastic Leukemia and Lymphoma during maintenance therapy.
    Barone T; Dandekar S; McKeone D; Mulieri K
    Cancer Rep (Hoboken); 2024 Feb; 7(2):e1987. PubMed ID: 38351548
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects on transmethylation by high-dose 6-mercaptopurine and methotrexate infusions during consolidation treatment of acute lymphoblastic leukemia.
    Keuzenkamp-Jansen CW; De Abreu RA; Blom HJ; Bökkerink JP; Trijbels JM
    Biochem Pharmacol; 1996 May; 51(9):1165-71. PubMed ID: 8645339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.
    Relling MV; Hancock ML; Boyett JM; Pui CH; Evans WE
    Blood; 1999 May; 93(9):2817-23. PubMed ID: 10216075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine.
    Erb N; Harms DO; Janka-Schaub G
    Cancer Chemother Pharmacol; 1998; 42(4):266-72. PubMed ID: 9744770
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Puangpetch A; Tiyasirichokchai R; Pakakasama S; Wiwattanakul S; Anurathapan U; Hongeng S; Sukasem C
    Pharmacogenomics; 2020 Apr; 21(6):403-410. PubMed ID: 32308129
    [No Abstract]   [Full Text] [Related]  

  • 31. Hepatotoxicity of 6-mercaptopurine in childhood acute lymphocytic leukemia: pharmacokinetic characteristics.
    Berkovitch M; Matsui D; Zipursky A; Blanchette VS; Verjee Z; Giesbrecht E; Saunders EF; Evans WE; Koren G
    Med Pediatr Oncol; 1996 Feb; 26(2):85-9. PubMed ID: 8531858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction.
    Schmiegelow K; Nielsen SN; Frandsen TL; Nersting J
    J Pediatr Hematol Oncol; 2014 Oct; 36(7):503-17. PubMed ID: 24936744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of mercaptopurine (6MP) metabolites and 6MP metabolic key-enzymes in childhood acute lymphoblastic leukemia.
    Wojtuszkiewicz A; Barcelos A; Dubbelman B; De Abreu R; Brouwer C; Bökkerink JP; de Haas V; de Groot-Kruseman H; Jansen G; Kaspers GL; Cloos J; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):422-33. PubMed ID: 24940700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Severe Recurrent Nocturnal Hypoglycemia During Chemotherapy With 6-mercaptopurine in 2 Children With Acute Lymphoblastic Leukemia.
    Albiroty K; Al Sabahi A
    J Pediatr Hematol Oncol; 2023 Apr; 45(3):162-163. PubMed ID: 36706266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic Exposure to Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic Leukemia: A Children's Oncology Group Study.
    Bhatia S; Landier W; Hageman L; Chen Y; Kim H; Sun CL; Kornegay N; Evans WE; Angiolillo AL; Bostrom B; Casillas J; Lew G; Maloney KW; Mascarenhas L; Ritchey AK; Termuhlen AM; Carroll WL; Wong FL; Relling MV
    JAMA Oncol; 2015 Jun; 1(3):287-95. PubMed ID: 26181173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia.
    Gervasini G; de Murillo SG; Jiménez M; de la Maya MD; Vagace JM
    Gene; 2017 Sep; 628():72-77. PubMed ID: 28710036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial.
    Vora A; Mitchell CD; Lennard L; Eden TO; Kinsey SE; Lilleyman J; Richards SM; ;
    Lancet; 2006 Oct; 368(9544):1339-48. PubMed ID: 17046466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acral Skin Rash Caused by Altered Mercaptopurine Metabolism in Maintenance Therapy for B-Cell Acute Lymphoblastic Leukemia.
    Newcome J; Geib KB; Thompson P; Gold S; Alexander TB
    J Pediatr Hematol Oncol; 2022 Oct; 44(7):398-401. PubMed ID: 35180762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology.
    Schmiegelow K; Schrøder H; Gustafsson G; Kristinsson J; Glomstein A; Salmi T; Wranne L
    J Clin Oncol; 1995 Feb; 13(2):345-51. PubMed ID: 7531219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma.
    Hedeland RL; Hvidt K; Nersting J; Rosthøj S; Dalhoff K; Lausen B; Schmiegelow K
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):485-91. PubMed ID: 19956952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.